幼年性息肉病综合征患者胃癌发生率的系统评价与荟萃分析
该系统评价与荟萃分析纳入11项研究共637例幼年性息肉病综合征患者,汇总胃癌发生率为3.5%(95%CI 1.8-5.2;I²=12.3%),中位年龄42.5岁。SMAD4致病性胚系变异携带者胃癌汇总发生率为10.1%(95%CI 3.2-16.8%;I²=54.7%),BMPR1A变异携带者仅报告1例,无可识别致病性胚系变异者未报告胃癌。作者认为SMAD4相关JPS胃癌风险最高,建议所有JPS患者行胚系检测以指导胃癌风险讨论和监测效用。
要点
- JPS患者胃癌汇总发生率为3.5%(95%CI 1.8-5.2),中位年龄42.5岁。
- SMAD4致病性胚系变异携带者胃癌汇总发生率为10.1%(95%CI 3.2-16.8%)。
- 无可识别致病性胚系变异者未报告胃癌,BMPR1A变异携带者仅报告1例。
核心结论
- 胃癌在SMAD4相关JPS中发生率最高,在无可识别致病性胚系变异的患者中未报告胃癌。
- BMPR1A致病性胚系变异携带者及无可识别致病性胚系变异的JPS患者行胃癌监测的价值存疑。
- 作者建议所有JPS患者行胚系检测,以指导胃癌风险讨论和监测效用。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、Embase和Scopus数据库,纳入报告JPS上消化道表现的研究。
- 共纳入11项研究、637例患者。
- 主要结局为JPS中报告的胃癌发生率,并按致病性胚系变异状态进行比较。
主要发现
- 胃癌汇总发生率为3.5%(95%CI 1.8-5.2;I²=12.3%),中位年龄42.5岁(范围15-57.6岁)。
- SMAD4致病性胚系变异携带者胃癌汇总发生率为10.1%(95%CI 3.2-16.8%;I²=54.7%)。
- BMPR1A致病性胚系变异携带者仅报告1例胃癌,无可识别致病性胚系变异者未报告胃癌。
- 在接受过胚系检测的患者中,SMAD4致病性胚系变异携带者胃癌风险高于无SMAD4致病性胚系变异者(OR 11.6;95%CI 4.6-29.4;I²=18.3%)。
- 胚系检测状态未知的JPS患者胃癌汇总发生率为7.5%(95%CI 0-15.5)。
关键数值与推荐
- SMAD4致病性胚系变异携带者胃癌汇总发生率10.1%(95%CI 3.2-16.8%;I²=54.7%)。
- SMAD4致病性胚系变异携带者较无SMAD4致病性胚系变异者胃癌风险OR 11.6(95%CI 4.6-29.4;I²=18.3%)。
- 无可识别致病性胚系变异者未报告胃癌;BMPR1A致病性胚系变异携带者仅报告1例胃癌。
临床怎么用
- 作者建议所有JPS患者行胚系检测,以指导胃癌风险讨论和监测效用。
- 作者认为BMPR1A致病性胚系变异携带者及无可识别致病性胚系变异的JPS患者行胃癌监测的价值存疑。
局限性
- 纳入研究总体存在中等偏倚风险。
- SMAD4致病性胚系变异携带者胃癌汇总发生率分析异质性I²=54.7%。
- 胚系检测状态未知的JPS患者胃癌汇总发生率95%CI为0-15.5。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The true rate of gastric cancer (GC) in juvenile polyposis syndrome (JPS) is unknown because of its rarity and ascertainment bias in published literature. To better assess this, we conducted a systematic review and meta-analysis. METHODS: MEDLINE, Embase, and Scopus databases were searched for the key words juvenile polyposis syndrome, juvenile polyps, stomach cancer, GC, SMAD4, BMPR1A, hamartomatous polyposis syndrome, hamartomas, and hereditary cancers for studies reporting upper GI manifestations in JPS. The primary outcome was the reported occurrence of GC in JPS. We then compared GC occurrence based on the presence or absence of pathogenic germline variants (PGVs) and in untested patients. RESULTS: Eleven studies including 637 patients were included. The pooled occurrence of GC was 3.5% (95% confidence interval [CI], 1.8-5.2; I2 = 12.3%) at a median age of 42.5 years (range, 15-57.6). The pooled occurrence of GC in patients with SMAD4 PGV was 10.1% (95% CI, 3.2-16.8%; I2 = 54.7%). GC was reported in only 1 BMPR1A PGV carrier and was not reported in patients without an identifiable PGV. In patients with prior germline testing, the risk of GC was higher in SMAD4 PGV carriers (odds ratio, 11.6; 95% CI, 4.6-29.4; I2 = 18.3%) compared with patients without SMAD4 PGV. In JPS patients with unknown status of germline testing, pooled occurrence of GC was 7.5% (95% CI, 0-15.5). There was an overall moderate risk of bias in the studies. CONCLUSIONS: GC is highest in SMAD4-associated JPS and was not reported in patients without identifiable PGVs. The value of GC surveillance in BMPR1A PGV carriers and JPS patients without an identifiable PGV is questionable. Germline testing should be performed in all JPS patients to inform GC risk discussion and utility of surveillance.
引用
- Singh AD, Gupta A, Mehta N, et al. Occurrence of gastric cancer in patients with juvenile polyposis syndrome: a systematic review and meta-analysis. Gastrointest Endosc. 2022. PMID: 36265529. doi:10.1016/j.gie.2022.10.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。